Role of nitric oxide in obsessive-compulsive behavior and its involvement in the anti-compulsive effect of paroxetine in mice

Nitric Oxide - Biology and Chemistry

Volumn 21, Issue 2, 2009, Pages 140-147

  Umathe, S N ^a   Bhutada, P S ^a   Jain, N S ^b   Mundhada, Y R ^a   Borkar, S S ^a   Dhumal, B ^b  

^a RTM NAGPUR UNIVERSITY   (India)

^b JL Chaturvedi College of Pharmacy   (India)

Author keywords

7 Nitroindazole; l Arginine; Marble burying behavior; Nitric oxide; Obsessive compulsive disorder; Paroxetine; Sildenafil; Sodium nitroprusside

Indexed keywords

7 NITROINDAZOLE; ARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRITE; NITROPRUSSIDE SODIUM; PAROXETINE; SILDENAFIL;

AMPEROMETRY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ARGININE; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; MALE; MICE; MOTOR ACTIVITY; NITRIC OXIDE; NITROPRUSSIDE; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE;

ANIMALIA; MUS;

EID: 68249144752     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2009.07.001     Document Type: Article

References (49)

1. Rasmussen S.A., and Eisen J.L. The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatr. Clin. North Am. 15 (1992) 743-758
2. Sasson Y., Zohar J., Chopra M., Lustig M., Iancu I., and Hendler T. Epidemiology of obsessive-compulsive disorder: a world view. J. Clin. Psychiatry 58 (1997) 7-10
3. Fontenelle L.F., Mendlowicz M.V., and Versiani M. The descriptive epidemiology of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 327-337
4. Pallanti S., and Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 400-412
5. Denys D., Zohar J., and Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry 65 (2004) 11-17
6. Bolton J., Moore G.J., MacMillan S., Stewart C.M., and Rosenberg D.R. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. J. Am. Acad. Child. Adolesc. Psychiatry 40 (2001) 903-906
7. Chakrabarty K., Bhattacharyya S., Christopher R., and Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30 (2005) 1735-1740
8. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., and Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J. Am. Acad. Child Adolesc. Psychiatry 39 (2000) 1096-1103
9. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr. Clin. North Am. 29 (2006) 553-584
10. Fineberg N.A., Gale T.M., and Sivakumaran T. A review of antipsychotics in the treatment of obsessive-compulsive disorder. J. Psychopharmacol. 20 (2006) 97-103
11. Kaplan A., and Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr. Serv. 54 (2003) 1111-1118
12. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., Saksa J., Wu Y.T., Gueorguieva R., Sanacora G., Malison R.T., and Krystal J.H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiatry 58 (2005) 424-428
13. Pasquini M., and Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 1173-1175
14. Poyurovsky M., Weizman R., Weizman A., and Koran L. Memantine for treatment-resistant OCD. Am. J. Psychiatry 162 (2005) 2191-2192
15. Esplugues J.V. NO as a signaling molecule in the nervous system. Br. J. Pharmacol. 135 (2002) 1079-1095
16. Harkin A., Bruce K.H., Craft B., and Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice: acute treatments are active in the forced swim test. Eur. J. Pharmacol. 372 (1999) 207-213
17. Guimaraes F.S., Beijamini V., Moreira F.A., Aguiar D.C., and de Lucca A.C.B. Role of nitric oxide in brain regions related to defensive reactions. Neurosci. Biobehav. Rev. 29 (2005) 1313-1322
18. Angulo J., Peiro C., Sanchez-Ferrer C.F., Gabancho S., Cuevas P., Gupta S., and Saenz de Tejada I. Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavernosum tissue. Br. J. Pharmacol. 134 (2001) 1190-1194
19. Finkel M.S., Laghrissi-Thode F., Pollock B.G., and Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol. Bull. 32 (1996) 653-658
20. Luo L., and Tan R.X. Fluoxetine inhibits dendrite atrophy of hippocampal neurons by decreasing nitric oxide synthase expression in rat depression model. Acta Pharmacol. Sin. 22 (2001) 865-870
21. Wegener G., Volke V., Harvey B.H., and Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res. 959 (2003) 128-134
22. Yaron I., Shirazi I., Judovich R., Levartovsky D., Caspi D., and Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 42 (1999) 2561-2568
23. Hashioka S., Klegeris A., Monji A., Kato T., Sawada M., McGeer P.L., and Kanba S. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp. Neurol. 206 (2007) 33-42
24. Fujiyama F., and Masuko S. Association of dopaminergic terminals and neurons releasing nitric oxide in the rat striatum: an electron microscopic study using NADPH-diaphorase histochemistry and tyrosine hydroxylase immunohistochemistry. Brain Res. Bull. 40 (1996) 121-127
25. Hidaka S., and Totterdell S. Ultrastructural features of the nitric oxide synthase-containing interneurons in the nucleus accumbens and their relationship with tyrosine hydroxylase-containing terminals. J. Comp. Neurol. 431 (2001) 139-154
26. Almeida R.C., Felisbino C.S., Lopez M.G., Rodrigues A.L., and Gabilan N.H. Evidence for the involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav. Brain Res. 168 (2006) 318-322
27. Hou Y., Wu C.F., Yang J.Y., He X., Bi X.L., Yu L., and Guo T. Effects of clozapine, olanzapine and haloperidol on nitric oxide production by lipopolysaccharide-activated N9 cells. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 1523-1528
28. Kato T., Monji A., Hashioka S., and Kanba S. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr. Res. 92 (2007) 108-115
29. Atmaca M., Tezcan E., Kuloglu M., and Ustundag B. Plasma nitrate values in patients with obsessive-compulsive disorder. Psychiatry Clin. Neurosci. 59 (2005) 621-623
30. Joel D. Current animal models of obsessive-compulsive disorder: a critical review. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 374-388
31. Uday G., Pravinkumar B., Manish W., and Sudhir U. LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur. J. Pharmacol. 563 (2007) 155-159
32. Umathe S., Bhutada P., Dixit P., and Shende V. Increased marble-burying behavior in ethanol-withdrawal state: modulation by gonadotropin-releasing hormone agonist. Eur. J. Pharmacol. 587 (2008) 175-180
33. Umathe S.N., Kochar N.I., Jain N.S., and Dixit P.V. Gastrointestinal dysfunction in diabetic rats relates with a decline in tissue l-arginine content and consequent low levels of nitric oxide. Nitric oxide 20 (2009) 129-133
34. Giordano D., De Stefano M.E., Citro G., Modica A., and Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim. Biophys. Acta 1539 (2001) 16-27
35. Kraus M.M., and Prast H. Involvement of nitric oxide, cyclic GMP and phosphodiesterase 5 in excitatory amino acid and GABA release in the nucleus accumbens evoked by activation of the hippocampal fimbria. Neuroscience 112 (2002) 331-343
36. Jain N.K., Patil C.S., Singh A., and Kulkarni S.K. Sildenafil induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res. 909 (2001) 170-178
37. Sato Y., Zhao W., and Christ G.J. Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 (2001) R269-R278
38. Kurt M., Bilge S.S., Aksoz E., Kukula O., Celik S., and Kesim Y. Effect of sildenafil on anxiety in the plus-maze test in mice. Pol. J. Pharmacol. 56 (2004) 353-357
39. Yuan Z., Hein T.W., Rosa R.H., and Kuo L. Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition. Invest. Ophthalmol. Vis. Sci. 49 (2008) 720-725
40. Salloum F.N., Abbate A., Das A., Houser J., Mudrick C.A., Qureshi I.Z., Hoke N.N., Roy S.K., Brown W.R., Prabhakar S., and Kukreja R.C. Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H1398-H1406
41. El Mansari M., and Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 362-373
42. Segieth J., Pearce B., Fowler L., and Whitton P.S. Regulatory role of nitric oxide over hippocampal 5-HT release in vivo. Naunyn. Schmiedebergs Arch. Pharmacol. 363 (2001) 302-306
43. Smith J.C., and Whitton P.S. Nitric oxide modulates N-methyl-d-aspartate-evoked serotonin release in the raphe nuclei and frontal cortex of the freely moving rat. Neurosci. Lett. 291 (2000) 5-8
44. Wegener G., Volke V., and Rosenberg R. Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. Br. J. Pharmacol. 130 (2000) 575-580
45. Harkin A., Connor T.J., Walsh M., St John N., and Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 44 (2003) 616-623
46. Serra P.A., Rocchitta G., Esposito G., Delogu M.R., Migheli R., Miele E., Desole M.S., and Miele M. A study on the role of nitric oxide and iron in 3-morpholino-sydnonimine-induced increases in dopamine release in the striatum of freely moving rats. Br. J. Pharmacol. 134 (2001) 275-282
47. Trabace L., and Kendrick K.M. Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J. Neurochem. 75 (2000) 1664-1674
48. West A.R., and Galloway M.P. Nitric oxide and potassium chloride-facilitated striatal dopamine efflux in vivo: role of calcium-dependent release mechanisms. Neurochem. Int. 33 (1998) 493-501
49. Lin H.C., Kang B.H., Wan F.J., Huang S.T., and Tseng C.J. Reciprocal regulation of nitric oxide and glutamate in the nucleus tractus solitarii of rats. Eur. J. Pharmacol. 407 (2000) 83-89